Cargando…
JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
Janus kinase inhibitors [JAKi] are a new class of small molecule drugs that modulate inflammatory pathways by blocking one or more JAK receptors, and are increasingly being used in the treatment of immune-mediated diseases. Tofacitinib, a non-selective JAKi, is now approved for moderate-to-severe ul...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395307/ https://www.ncbi.nlm.nih.gov/pubmed/32006031 http://dx.doi.org/10.1093/ecco-jcc/jjaa017 |